PTC's novel cystic fibrosis drug shows benefit in Phase IIa
This article was originally published in Scrip
Executive Summary
PTC Therapeutics' PTC124, a novel investigational treatment for cystic fibrosis, is able to reduce the ion transport abnormalities seen in the condition, Phase IIa results suggest.